臨床検査63巻7号

2019年07月発行

今月の特集1 造血器腫瘍の遺伝子異常

急性骨髄性白血病の遺伝子異常

著者： 山口博樹¹

所属機関： ¹日本医科大学血液内科

ページ範囲：P.811 - P.817

Point

●急性骨髄性白血病（AML）はさまざまな染色体異常や遺伝子異常がその発症に関与しているheterogeneousな疾患である．

●AMLでは染色体異常や遺伝子変異によって予後を層別化し，同種造血幹細胞移植（allo-HSCT）の適応を決める．

●AMLにおいてFLT3 ITDは頻度が高く最も重要な予後不良因子である．

●AMLにおいてNPM1変異，CEBPA変異などが予後因子として重要となってきている．

参考文献

1）Miyawaki S：Clinical studies of acute myeloid leukemia in the Japan Adult Leukemia Study Group. Int J Hematol　96：171-177，2012

2）Döhner H, Estey EH, Amadori S, et al：Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood　115：453-474，2010

3）日本血液学会（監訳）：NCCN腫瘍学臨床診療ガイドライン　急性骨髄性白血病　2014年　第2版，臨床研究情報センター，2014（https://www2.tri-kobe.org/nccn/guideline/hematologic/japanese/aml.pdf）（最終アクセス：2019年3月28日）

4）Döhner H, Estey E, Grimwade D, et al：Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood　129：424-447，2017

5）Sakaguchi M, Yamaguchi H, Najima Y, et al：Prognostic impact of low allelic ratio FLT3-ITD and NPM1 mutation in acute myeloid leukemia. Blood Adv　2：2744-2754，2018

6）Kurosawa S, Yamaguchi H, Yamaguchi T, et al：The prognostic impact of FLT3-ITD, NPM1 and CEBPA mutation of the first relapse patients with intermediate-risk AML treated with chemotherapy alone, in press

7）Kurosawa S, Yamaguchi H, Yamaguchi T, et al：Decision Analysis of Postremission Therapy in Cytogenetically Intermediate-Risk Acute Myeloid Leukemia：The Impact of FLT3 Internal Tandem Duplication, Nucleophosmin, and CCAAT/Enhancer Binding Protein Alpha. Biol Blood Marrow Transplant　22：1125-1132，2016

8）Wakita S, Yamaguchi H, Ueki T, et al：Complex molecular genetic abnormalities involving three or more genetic mutations are important prognostic factors for acute myeloid leukemia. Leukemia　30：545-554，2016

9）Krönke J, Bullinger L, Teleanu V, et al：Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia. Blood　122：100-108，2013

10）Ryotokuji T, Yamaguchi H, Ueki T, et al：Clinical characteristics and prognosis of acute myeloid leukemia associated with DNA-methylation regulatory gene mutations. Haematologica　101：1074-1081，2016

11）Terada K, Yamaguchi H, Ueki T, et al：Full-length mutation search of the TP53 gene in acute myeloid leukemia has increased significance as a prognostic factor. Ann Hematol　97：51-61，2018

12）Wakita S, Yamaguchi H, Miyake K, et al：Importance of c-kit mutation detection method sensitivity in prognostic analyses of t(8;21)(q22;q22) acute myeloid leukemia. Leukemia　25：1423-1432，2011

13）Yui S, Kurosawa S, Yamaguchi H, et al：D816 mutation of the KIT gene in core binding factor acute myeloid leukemia is associated with poorer prognosis than other KIT gene mutations. Ann Hematol　96：1641-1652，2017

14）Shlush LI, Zandi S, Mitchell A, et al：Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature　506：328-333，2014

15）Genovese G, Kähler AK, Handsaker RE, et al：Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med　371：2477-2487，2014

16）Wakita S, Yamaguchi H, Omori I, et al：Mutations of the epigenetics-modifying gene (DNMT3a, TET2, IDH1/2) at diagnosis may induce FLT3-ITD at relapse in de novo acute myeloid leukemia. Leukemia　27：1044-1052，2013

17）Patel JP, Gönen M, Figueroa ME, et al：Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med　366：1079-1089，2012